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In order to determine the effect of antibodies against electronegative low-density lipoprotein LDL(-) on atherogenesis, five
groups of LDL low receptor-deficient (LDLr-/-) mice (6 per group) were immunized with the following antibodies (100 µg each):
mouse anti-LDL(-) monoclonal IgG2b, rabbit anti-LDL(-) polyclonal IgG or its Fab fragments and mouse irrelevant monoclonal
IgG and non-immunized controls. Antibodies were administered intravenously one week before starting the hypercholesterole-
mic diet (1.25% cholesterol) and then every week for 21 days. The passive immunization with anti-LDL(-) monoclonal IgG2b,
polyclonal antibody and its derived Fab significantly reduced the cross-sectional area of atherosclerotic lesions at the aortic root
of LDLr-/- mice (28.8 ± 9.7, 67.3 ± 17.02, 56.9 ± 8.02 µm2 (mean ± SD), respectively) compared to control (124.9 ± 13.2 µm2).
Vascular cell adhesion molecule-1 protein expression, quantified by the KS300 image-analyzing software, on endothelium and the
number of macrophages in the intima was also decreased in aortas of mice treated with anti-LDL(-) monoclonal antibody (3.5 ± 0.70 per
field x 10) compared to controls (21.5 ± 3.5 per field x 10). Furthermore, immunization with the monoclonal antibody decreased the
concentration of LDL(-) in blood plasma (immunized: 1.0 ± 1.4; control: 20.5 ± 3.5 RLU), the amount of cholesterol oxides in plasma
(immunized: 4.7 ± 2.7; control: 15.0 ± 2.0 pg COx/mg cholesterol) and liver (immunized: 2.3 ± 1.5; control: 30.0 ± 26.0 pg COx/mg
cholesterol), and the hepatic content of lipid hydroperoxides (immunized: 0.30 ± 0.020; control: 0.38 ± 0.15 ng/mg protein). In conclusion,
antibodies against electronegative LDL administered intravenously may play a protective role in atherosclerosis.
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Introduction
Modification of low-density lipoprotein (LDL) plays a
key role in atherosclerosis. A minimally modified circulat-
ing electronegative LDL subfraction, denoted LDL(-), is
increased in hypercholesterolemia and diabetes and
has been implicated in atherosclerosis progression (1,2).
LDL(-) particles have lower antioxidant content, increased
lipid peroxidation products, as well as conformational al-
terations of apoB (3,4). LDL(-) is cytotoxic to cultured
endothelial cells (5), promotes increased leukocyte re-
cruitment for inducing the release of IL-8 and monocyte
chemotactic protein 1 (6), impairs angiogenesis (7), and
has less affinity for the LDL receptor (3,8). Intravenous
injection of immunoglobulins is used as a therapy for
autoimmune and systemic inflammatory diseases (9,10).
In contrast, it has been suggested that antibodies reactive
to oxidized LDL (ox-LDL) may contribute to the pathogen-
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esis of atherosclerosis (11). However, anti-ox-LDL IgM anti-
bodies may protect against atherosclerosis possibly because
they can scavenge the ox-LDL particles (12). We report here
that the passive immunization with xenogeneic polyclonal
antibodies, xenogeneic Fab fragments, and allogeneic mono-
clonal antibodies IgG reactive to LDL(-) significantly reduced
atherosclerosis in LDLr-/- mice.
Material and Methods
Polyclonal antibodies reactive to LDL(-)
New Zealand rabbits were immunized by intramuscu-
lar injection every 2 weeks for 3 months with 50 µg LDL(-)
incorporated in Freund’s complete adjuvant for the first
injection and in incomplete Freund’s adjuvant for subse-
quent injections. LDL(-) was purified by fast protein liquid
chromatography (13). After purification, 1.0 mM EDTA, 5.0
mM phenylmethylsulfonyl fluoride, 10.0 µM benzamidine,
10.0 µg/mL aprotinine and 100.0 µM butylated hydroxytolu-
ene were added to the LDL(-) preparation and was main-
tained at 4°C. The production of anti-LDL(-) polyclonal anti-
body was monitored by ELISA. Antibodies were purified
from rabbit serum by affinity chromatography in a protein G
column (Hi Trap Protein-G, Pharmacia, Biotech, USA) (14).
ELISAs were carried out (15,16) using a SpectroCount
analyzer (Canberra Company, USA). Plates (EIA/RIA, Costar,
USA) were coated with 1 µg/mL purified native LDL and the
anti-LDL(-) monoclonal antibody was added after previ-
ously blocking the microplate wells with defatted milk. The
antibodies were cleaved by papain to obtain the Fab frag-
ments (17). Fragmentation was confirmed by 10% SDS-
PAGE on vertical slab gels according to Laemmli (18) with
silver nitrate staining (data not shown).
Purification of monoclonal antibody
The IgG2b anti-LDL(-) monoclonal antibody (MAb
3D1036) was obtained in our laboratory as described (3).
Briefly, the antibodies were obtained from the ascitic fluid
induced in BALB/c mice (6 to 10 weeks old) injected with
Pristane (Sigma, USA) before the inoculation of the
3D1036 hybridoma cells secreting the anti-LDL(-) MAb.
Ten days after this inoculation, the MAb was purified from
the ascitic fluid by affinity chromatography in a protein G
column (Hi Trap Protein-G, Pharmacia, Biotech, Sweden).
The MAb 3D1036 recognizes an epitope present in mini-
mally modified LDL particles as previously reported by
Damasceno et al. (2).
Passive immunization
Female C57BL/6 LDL receptor knockout mice (3
months old) were purchased from Jackson Laboratories
(USA). The following groups, with 6 animals each, were
studied: group 1 (controls), treated with PBS; group 2,
treated with 100 µg of an irrelevant MAb (IgG2b anti-18
kDa peptides of Taenia crassiceps); group 3, treated with
rabbit IgG polyclonal antibody (100 µg) against LDL(-);
group 4, treated with Fab fragments (100 µg) derived
from the rabbit polyclonal antibody reactive to LDL(-);
group 5, treated with IgG2b monoclonal antibody (100
µg) against LDL(-). Antibodies were administered intra-
venously once one week before starting the 1.25% cho-
lesterol-enriched diet and then every week for 21 days.
All procedures were in accordance with recomenda-
tions of the Institutional Committee for Ethics in Animal
Experimentation (CEEA/IB, UNICAMP, protocol #521-1,
Brazil), in agreement with the guidelines of the Brazilian
College for Animal Experimentation.
Tissue preparation and histomorphometry of aortic root
lesions
The heart was perfused with PBS and then with 10%
PBS-buffered formaldehyde. The heart and aorta were
excised and fixed in 10% formaldehyde for at least 2 days,
and then embedded in 5, 10, and 25% gelatin and frozen in
mounting medium (Tissue-Tek OTC compound, Sakura
Finetek, USA). The aortic root in the heart was sectioned
proximally to distally in 10 µm starting from the semilunar
valves. The area of the atherosclerotic lesion was reported
as the sum of the lesion in 6 equidistant sections (80 µm)
from each other in an aortic root length of 400 µm. Results
from 6 mice/group are reported as mean µm2 ± SD. To
quantify the ross-sectional area of the oil red O-stained
lesions in the aortic root, processing and staining were
carried out as described (19), using the Image Pro Plus
software (version 3.0) for image analysis (Media Cybernet-
ics, USA). All analyses were double-blind and carried out
independently by two observers.
Immunohistochemical and histochemical analyses
To evaluate the vascular cell adhesion molecule-1
(VCAM-1), the remaining thoracic and abdominal aortas
were mounted with Tissue-Tek OTC compound, frozen in
isopentane and embedded in paraffin. VCAM-1 was de-
tected with an anti-VCAM antibody (Santa Cruz Biotechnol-
ogy, H-276, USA) (20). VCAM-1 staining was quantified
using an image-analyzing software (KS300, Kontron, Ger-
many). The histochemical analysis of the aorta was done in
5-µm thick tissue sections stained with hematoxylin/eosin.
The number of foam cells was estimated as described (21).
Detection of LDL(-) in blood plasma and autoantibodies
At the end of the experiment, blood was collected from
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the ocular-plexus and plasma was obtained by centrifuga-
tion. LDL(-) was determined by ELISA with Fab fragments
derived from rabbit anti-LDL(-) polyclonal IgG as the cap-
ture antibody. A biotinylated anti-LDL(-) monoclonal anti-
body was added as secondary antibody and streptavidin–
horseradish peroxidase conjugate was used for quantita-
tion. The positive reaction was evaluated by chemilumines-
cence and the concentration of LDL(-) was determined
using a standard curve made with purified LDL(-) (22).
Anti-LDL(-) autoantibodies were determined by direct
ELISA. Plasma samples (50 µL/well) previously diluted in
PBS (1:50) were assayed. An anti-mouse IgG/horseradish
peroxidase conjugate (Bio-Rad, USA) was used for detec-
tion and quantitation using standard procedures. The re-
action was evaluated colorimetrically at 492 nm using a
SpectroCount analyzer (Canberra Company). All experi-
ments were carried out in triplicate.
Analysis of lipid peroxidation
Lipid hydroperoxides were extracted from the liver and
the cholesterol oxides (COx) were extracted from both liver
and plasma of LDLr-/- mice as described by Pereira et al.
(23).
Statistical analysis
ANOVA and the Tukey-Kramer test were used to ana-
lyze the data statistically. All values are reported as mean ±
SD. Statistical significance was considered to be P < 0.05.
Results
Atherosclerotic lesions
The passive immunization of LDLr-/- mice with the anti-
LDL(-) monoclonal (IgG2b isotype) and IgG polyclonal
(whole or its Fab fragments) antibodies decreased the
cross-sectional area of atherosclerotic lesions at the aortic
root compared with controls (Figure 1). Immunization with
the anti-LDL(-) MAb did not change the total plasma cho-
lesterol concentration compared to the control group (im-
munized: 46.6 ± 18.7; control: 60.5 ± 13.6 mg/mL total
cholesterol). The protective effect of the anti-LDL(-) mono-
clonal IgG2b was greater than that of the polyclonal IgG
and irrelevant monoclonal antibody for reducing both the
cross-sectional area (Figure 1A) and the number of foam
cells in the atherosclerotic lesions (Figure 1B). Figure 2
shows the oil red-stained sections of atherosclerotic le-
sions at the aortic root of mice immunized with the same
antibodies as shown in Figure 1.
Expression of vascular cell adhesion molecule-1
Mice receiving the Fab fragments derived from the
Figure 1. Atherosclerotic lesions of low-density lipoprotein re-
ceptor-deficient (LDLr-/-) mice treated with antibodies against
LDL(-). A, Cross-sectional area of atherosclerotic lesions at the
aortic root of LDLr-/- mice; B, number of foam cells in the subin-
timal layer of atherosclerotic lesions of LDLr-/- mice treated or
not with anti-LDL(-) monoclonal antibody (MAb, 100 µg), irrel-
evant Mab (100 µg), rabbit polyclonal anti-LDL(-) antibody (100
µg) and Fab fragments from rabbit anti-LDL(-) polyclonal anti-
body (100 µg). P < 0.05, ANOVA followed by the Tukey-Kramer
test.
rabbit anti-LDL(-) polyclonal antibody showed the largest
decrease of VCAM-1 expression in aorta sections than
those receiving the whole antibody and non-immunized
control mice (Figure 3).
Concentration of free LDL(-) and autoantibodies
The passive immunization of LDLr-/- mice with anti-
LDL(-) monoclonal IgG2b decreased the circulating levels
of free LDL(-) and also increased free anti-LDL(-) IgG
antibodies in relation to the non-immunized controls and
irrelevant antibody (Figure 4A and B). In contrast, immuni-
zation with the anti-LDL(-) polyclonal IgG enhanced the
levels of free LDL(-) and decreased the levels of free anti-
LDL(-) IgG antibodies in blood plasma compared with the
non-immunized controls. The administration of Fab frag-
ments derived from the anti-LDL(-) polyclonal IgG antibody
did not affect any of the parameters evaluated when com-
pared with the control non-immunized mice.
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Figure 2. Atherosclerotic le-
sions in aortic valve of low-den-
sity lipoprotein receptor-defi-
cient (LDLr-/-) mice. Aorta sec-
tions of A, control mice; B, mice
treated with anti-LDL(-) polyclo-
nal antibody (100 µg); C, mice
treated with Fab fragments from
anti-LDL(-) polyclonal antibody
(100 µg); D, mice treated with
anti-LDL(-) monoclonal antibody
(100 µg). The sections were
stained with oil red O and the
arrows indicate the build-up of
plaque within the aorta. Magni-
fication: 4X and 40X.
Figure 3. Immunohistochemistry staining of vascular cell adhe-
sion molecule-1 (VCAM-1) in sections of the aorta of low-density
lipoprotein receptor-deficient (LDLr-/-) mice not treated or treated
with irrelevant monoclonal antibody (MAb, 100 µg), anti-LDL(-)
MAb (100 µg), rabbit anti-LDL(-) polyclonal antibody (100 µg) or
Fab fragments from rabbit anti-LDL(-) polyclonal antibody (100
µg). Percent of VCAM-1-positive staining on aorta sections was
evaluated using image-analyzing software (KS300, Kontron). P
< 0.05, ANOVA followed by the Tukey-Kramer test.
Figure 4. Determination of electronegative low-density lipoprotein [LDL(-)] and its autoantibodies in blood plasma of low-density
lipoprotein receptor-deficient (LDLr-/-) mice not treated or treated with irrelevant monoclonal antibody (MAb, 100 µg), anti-LDL(-) MAb
(100 µg), rabbit anti-LDL(-) polyclonal antibody (100 µg) or Fab fragments from rabbit anti-LDL(-) polyclonal antibody (100 µg). A,
Concentration of LDL(-). B, Levels of free circulating antibodies (Ab) reactive to LDL(-). P < 0.05, ANOVA followed by the Tukey-Kramer
test.
A B
C D
4X
4X
4X 4X
40X
40X
40X
40X
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Lipid peroxidation
Passive immunization of LDLr-/- mice with the anti-
LDL(-) IgG2b MAb reduced the concentrations of COx in
plasma (immunized: 4.7 ± 2.7; irrelevant control 14.7 ±
2.1; control: 15.0 ± 2.0 pg COx/mg cholesterol) and liver
by 70 and 92%, respectively (immunized: 2.3 ± 1.5; irrel-
evant control 31 ± 26; control: 30.0 ± 26.0 pg COx/mg
cholesterol), as well as 21% of hepatic lipid hydroperox-
ides (immunized: 0.30 ± 0.020; irrelevant control: 0.40 ±
0.16; control: 0.38 ± 0.15 ng/mg protein) compared with
non-immunized control mice.
Discussion
The most important finding of this study was that pas-
sive immunization of LDLr-/- mice with monoclonal and
polyclonal antibodies against LDL(-) decreases the cross-
sectional area of lipid-stained atherosclerosis plaques in
the aortic root. Our data showed that the monoclonal
antibody (IgG2b) was more atheroprotective even when
compared with the polyclonal antibody. This may be re-
lated to the recognition of the rabbit-derived polyclonal
antibody as non-self by murine immune system.
LDLr-/- mice treated with anti-LDL(-) monoclonal anti-
body had lower levels of circulating free LDL(-) than the
non-immunized mice or mice immunized with irrelevant
monoclonal antibody. Thus, considering that passive im-
munization with IgG2b anti-LDL(-) monoclonal antibody
had a protective effect on atherosclerotic plaque develop-
ment, it is possible that the decreased levels of free
LDL(-) in blood plasma were due to the formation of
immune complexes between LDL(-) and the monoclonal
antibody injected in mice. We also observed an inverse
relationship between circulating free LDL(-) and free anti-
LDL(-) antibodies in mice treated with anti-LDL(-) mono-
clonal antibody. This high level of free IgG antibodies
reactive to LDL(-) probably reflects endogenous autoanti-
bodies plus the exogenous injected antibody since an
anti-mouse IgG-conjugate was used in ELISA. This vali-
dated the passive immunization with this monoclonal
antibody, since the mean half-life of mouse IgG is 14 days
and a considerable amount of free anti-LDL(-) mono-
clonal antibody would be expected to remain in the circu-
lation 7 days after the last injection. In contrast, for mice
treated with rabbit anti-LDL(-) polyclonal antibodies, an
immune response of these animals against the Fc por-
tion of rabbit IgG could contribute to induce the genera-
tion of mouse antibodies against rabbit IgG-LDL(-) im-
mune complexes. Thus, these high levels of antibodies
could affect the detection of free anti-LDL(-) antibodies by
ELISA in the plasma of these mice. The administration of
Fab fragments derived from the rabbit anti-LDL(-) poly-
clonal antibody did not affect the concentration of free
autoantibodies reactive to LDL(-). This was probably be-
cause Fab fragments retain the ability to bind to LDL(-)
epitopes while they lose the binding region to Fc of mouse
immunoglobulins. Thus, the free mouse autoantibodies
remain in circulation. The presence of anti-LDL(-) auto-
antibodies in non-immunized LDLr-/- mice indicates that
the endogenous humoral immune response was not
atheroprotective since in these animals the atheroscle-
rotic lesions were more accentuated compared with im-
munized mice. Another possible explanation is that the
titer of endogenous antibodies was not enough and once
400 µg of additional anti-LDL(-) was added by adoptive
transfer an atheroprotective effect was attained.
In vivo studies have suggested that macrophage death
in early lesions decreases macrophage burden and slows
lesion progression (24,25). The live macrophages may
promote late lesional complications by secreting inflam-
matory mediators (26). In the present study, mice treated
with anti-LDL(-) monoclonal IgG2b had less foam cells in
the subintimal layer of atherosclerotic lesions compared
with control mice. These observations are consistent with
other studies showing that immunization with human IgG1
against malondialdehyde (MDA)-peptide sequences re-
duced atherosclerosis in apoE-/- mice associated with a
decreased number of macrophages in atherosclerotic
plaques (27). Probably the monoclonal antibody anti-
LDL(-) neutralized circulating LDL(-) and avoided its ef-
fects on endothelium including the release of monocyte
chemotactic factors, the entrance of these cells into the
artery wall and their differentiation to macrophages.
The removal of LDL(-) by anti-LDL(-) monoclonal
IgG2b decreased the formation of lipid peroxidation prod-
ucts in plasma and liver of LDLr-/- mice, suggesting an
additional atheroprotective effect of this passive immuni-
zation. Moreover, the decreased concentration of choles-
terol oxides in plasma of anti-LDL(-) monoclonal anti-
body-treated mice may also be a consequence of LDL(-)
removal from blood circulation since these minimally
modified particles have an increased content of lipid per-
oxidation products (5).
The expression of adhesion molecules in arterial endo-
thelial cells occurs during the early phases of diet-induced
atherogenesis (28,29). In the present study, VCAM-1 ex-
pression was reduced after treating LDLr-/- mice with the
Fab fragment derived from the anti-LDL(-) polyclonal anti-
body. One reason is that endothelial cells express Fc gam-
ma receptors (30) and, thus, the absence of the Fc portion
in the Fab fragment would not induce the activation of
endothelial cells leading to decreased VCAM expression.
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We have shown for the first time that antibodies against
LDL(-) administered intravenously can play a protective
role in atherosclerosis. Although the mechanisms involved
in this atheroprotection have not yet been elucidated, our
results point to the importance of immune responses against
oxidized LDL in atherosclerosis and the possibility that the
antibodies against modified LDL could be used to assess
disease activity, as well as a therapeutic strategy for the
prevention of atherosclerosis.
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